Press Release
RainDance Technologies CEO to Present at Transformational Tools Panel During 2009 BIO International Convention
LEXINGTON, MASSACHUSETTS, U.S.A., May 5, 2009 -- Christopher McNary, RainDance Technologies President and Chief Executive Officer, will discuss the impact of new transformational tools shaping life sciences research during a panel session at the 2009 BIO International Convention in Atlanta on May 20, 2009.
The session, Transformational Tools: How New Research Technologies Are Changing the Rules of the Game, will review how the accessibility and power of these new tools are empowering individual scientists to conduct research that was formerly infeasible, unaffordable, or threatening to the research status quo.
In his remarks, McNary will discuss how exciting new technologies are enabling researchers to rethink the way they design experiments and approach discovery, permitting the achievement of previously unattainable breakthrough science. He will cite that the capabilities of his company’s RainStorm™ microdroplet-based technology platform can be applied across a wide range of biomedical research applications. For example, McNary will describe how a researcher can collect a heterogeneous group of cells of interest, such as a cancer sample, break it down into homogeneous collections of primary cells such as tumor and stem cells, capture and interrogate these as single cells, and perform scientific analyses. This capability will help make exciting strides in understanding the fundamental biology of complex disease.
In addition, McNary will explain how the RainStorm platform also is being applied in collaboration with sanofi-aventis to develop game-changing high-throughput screening methodologies for drug discovery. This work will accelerate the discovery process by enabling pharmaceutical companies to make better and faster decisions about what compounds should be pulled through their development pipelines. McNary will review how these new workflows minimize experimental unknowns, permit simple sample manipulation, and generate accurate measurements at levels unimaginable only a few years ago.
McNary and the other chief executives on the panel also will describe the radical innovations, new perspectives, and diverse disciplines underlying these new technologies, as well as challenges to development and commercialization.
To learn more, visit the RainDance Technologies Website at www.raindancetech.com, or call 781-861-6300.
For more information about the 2009 BIO International Convention, visit http://convention.bio.org/.
About RainDance Technologies, Inc.
RainDance's proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical diagnostics. The core RainStorm™ technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible, and low-cost manner. RainDance's commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. RainDance sells directly in the U.S. and in Europe, and is building distribution networks in Europe and Asia-Pacific. RainDance Technologies has approximately 70 employees worldwide. For more information, please visit www.raindancetech.com.
RainStorm is a trademark of RainDance Technologies, Inc.
For corporate questions contact:
Chris McNary
RainDance Technologies
44 Hartwell Avenue
Lexington, MA 02421
Phone — 781-861-6300
mcnaryc@raindancetech.com
For technical questions contact:
James Brayer
RainDance Technologies
44 Hartwell Avenue
Lexington, MA 02421
Phone — 781-861-6300
info@raindancetech.com
For press inquiries:
Colin Sanford
Phone — 203-340-2441
colin@bioscribe.com
